SCHEMBL5606028

SCHEMBL5606028

O=C(O)C1CCN(C(=O)CCCN2CCOCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.48
POLB P06746 1/20 0.47
GLA P06280 2/20 0.46
TSHR P16473 2/20 0.45
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HTR7 P34969 3/20 0.42
HTR1A P08908 1/20 0.42
KDM4E B2RXH2 1/20 0.41
RAB9A P51151 1/20 0.40
PKM P14618 1/20 0.40
EPHX1 P07099 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3959932 0.84 GNAI3 (0.54) KDM1AGLATSHRALOX15HSD17B10
SCHEMBL3960579 0.82 KDM1A (0.54) KDM1AGLATSHRALOX15HSD17B10
SCHEMBL5605817 0.81 ALDH1A1 (0.57) POLBTSHRHSD17B10LMNANPC1
SCHEMBL19074082 0.79 PDCD1 (0.50) KDM1AGLATSHRALOX15HSD17B10
SCHEMBL14072805 0.78 KDM1A (0.50) KDM1AGLATSHRALOX15HSD17B10
SCHEMBL17284638 0.78 KDM1A (0.52) KDM1APOLBGLATSHRALOX15
SCHEMBL17285955 0.78 NPC1 (0.60) KDM1APOLBGLATSHRLMNA
SCHEMBL22878226 0.78 KDM1A (0.52) KDM1APOLBGLATSHRALOX15
SCHEMBL4499189 0.77 LMNA (0.49) KDM1AGLATSHRALOX15HSD17B10
SCHEMBL5605682 0.76 EPHX1 (0.49) GLALMNAALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166594-B2 Antibacterial activity AVENTIS PHARMA S.A. (FR) 2007-01-23 US disclosed
EP-1187847-B1 STREPTOGRAMIN DERIVATIVES, PREPARATION AND COMPOSITIONS CONTAINING THEM AVENTIS PHARMA SA (FR) 2003-12-03 EP disclosed
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. 2003-08-07 US disclosed
US-6569854-B1 Virginamycins AVENTIS PHARMA S.A. (FR) 2003-05-27 US disclosed
EP-1187847-A1 STREPTOGRAMIN DERIVATIVES, PREPARATION AND COMPOSITIONS CONTAINING THEM Aventis Pharma S.A. (FR) 2002-03-20 EP disclosed
WO-2001002427-A1 STREPTOGRAMIN DERIVATIVES, PREPARATION AND COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149004-A1 Streptogramin derivatives, their preparation and compositions containing them MRPL21, ABHD5, APEH KDM1A 3370/4885POLB 2117/4885GLA 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.